Your SlideShare is downloading. ×
  • Like
Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

  • 394 views
Published

Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms …

Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020.


Source : http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

Published in Health & Medicine
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
394
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
5
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Transparency Market ResearchPeptide Therapeutics Buy NowMarket - Global Industry Request SampleAnalysis, Size, Share,Growth, Trends And Published Date: Mar 2013Forecast, 2012 – 2018 Single User License: US $ 4595 128 Pages Report Multi User License: US $ 7595 Corporate User License: US $ 10595 REPORT DESCRIPTION Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 – 2018 The Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules since chemotherapy, which is the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly. In addition, it affects the normal cells in the body.
  • 2. Browse Report : Peptide Therapeutics MarketLikewise, peptide application in various other treatments has opened a promising avenue forfuture growth of this market. New routes of peptide administration are being investigated;however the parenteral route continues to dominate this market and accounted for a shareof almost 86% of the entire market. Similarly, the technology market is ruled by LPPS (longphase peptide syntheses) and is anticipated to decline owing to huge demand for solidphase peptide syntheses and hybrid syntheses.This report analyzes the peptide therapeutics market by types of applications (cancer,metabolic, neurological diseases and others), route of administration, by types (innovativeand generic), by API therapeutics market (in-house vs. CMO), by peptide therapeutics, andtechnology. Each of these markets is analyzed by studying the current and future marketscenario, with estimation for the period 2010 – 2018 in terms of value in USD million.The peptide therapeutics market is also segmented based on geography into North America,Europe, Asia and rest of the world (RoW) regions. The market for all these geographicalregions is provided in the report in terms of revenue. The report provides complete analysisof the factors responsible for driving and restraining the global peptide therapeuticsmarket.Competitive landscape is provided with market players profiled with attributes like companyoverview, financial overview, business strategies, product portfolio and recentdevelopments. Market shares in 2011 for the key players and CMO players are provided andrecommendations to accentuate market shares and ensure sustainability are provided inthis reportKey market players profiled in this report are Eli Lilly, Roche, Amylin, Novo-Nordisk, Ipsenand others. While CMOs major players profiled are Bachem, Lonza, Peptisyntha, Polypeptidegroup and others.Peptide Therapeutics Market, by Applications  Cancer  Metabolic  Cardiovascular  Dermatology  Anti-Infection  Neurology  Gastro Intestinal  Renal
  • 3.  Respiratory  Pain  OthersPeptide Therapeutics Market, by Route of Administration  Parenteral  Oral  Pulmonary  Mucosal  OthersPeptide Therapeutics Market, by Types  Innovative  GenericsPeptide Therapeutics Market, by API Peptide  In-House  CMO (Contract Manufacturing Organization)Peptide Therapeutics by Technology  Liquid Phase Peptide Synthesis (LPPS)  Solid Phase Peptide Synthesis (SPPS)  HybridPeptide Therapeutics Market, by Geography  North America  Europe  Asia  RoWBrowse Report : http://www.transparencymarketresearch.com/peptide-therapeutics-market.html
  • 4. TABLE OF CONTENTSChapter 1 Preface1.1 Report description1.2 Market segmentation1.3 Scope of the report1.4 Research methodology1.5 AssumptionsChapter 2 Executive Summary2.1.1 Global peptide therapeutics market revenues, 2010 – 2018 (USD Million)2.1.2 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million)2.1.3 Global API peptide therapeutics market, 2011 (USD Million)2.1.4 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%)Chapter 3 Global Peptide Therapeutics Market Dynamics3.1 Overview3.2 Drivers3.2.1 Increase in cancer patient population to propel the growth of new peptides3.2.2 Rise in metabolic disorders to escalate the growth of peptides market3.2.3 Rise in R&D pipeline of peptide drugs is expected to bring considerable growth incoming years3.2.3.1 Global peptide therapeutics trials growth, 1970 - 20113.2.4 Technological enhancement has boosted the growth of the market with radicalreduction in total production cost of peptides3.3 Restraints & challenges3.3.1 Increasing complexity of peptides is a huge challenge for manufacturers3.3.2 Lack of regulatory standards hampering the growth of the market
  • 5. 3.3.3 Matching equipments with customer requirements is a major challenge for API peptidemanufacturers3.4 Opportunities3.4.1 Rise in cancer vaccine to drive the future market3.4.2 Generic peptides market to flourish with patent cliff expected in the forecast period3.4.3 Small biotech firms collaborating with large pharmaceutical companies to explorefurther growth3.4.3.1 Global scenario of acquisitions of biotech firms by large pharma giants3.4.3.2 Major peptide drugs and sales, 2011 (USD Million)3.5 Porters five forces analysis3.5.1 Porter’s five forces analysis of global peptide therapeutics market3.5.2 Bargaining power of suppliers3.5.3 Bargaining power of buyers3.5.4 Threat of new entrants3.5.5 Threat of substitutes3.5.6 Competitive rivalry3.6 Market attractiveness analysis3.6.1 Market attractiveness analysis of the peptide therapeutics market by geography3.7 Peptide therapeutics - emerging technologies & trends3.8 Regulatory policiesChapter 4 Global Peptide Therapeutics Market Analysis, By Applications4.1.1 Introduction4.1.1.1 Global peptide therapeutics market revenue, by applications 2012-2018 (USDMillion)4.1.2 Cancer4.1.2.1 Global cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 -20124.1.2.2 Global cancer peptide therapeutics market revenues, 2010 – 2018 (USD Million)
  • 6. Browse Report : http://www.transparencymarketresearch.com/peptide-therapeutics-market.html4.1.3 Metabolic4.1.3.1 Global metabolic peptide therapeutics pipeline drugs analysis, number of trials,2009 - 20124.1.3.2 Global metabolic peptide therapeutics market revenues, 2010 – 2018 (USD Million)4.1.4 Cardiovascular4.1.4.1 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials,2009 - 20124.1.4.2 Global cardiovascular peptide therapeutics market revenues, 2010 – 2018 (USDMillion)4.1.5 Dermatology4.1.5.1 Global dermatology pipeline drugs analysis, number of trials, 2009 - 20124.1.5.2 Global dermatology peptides market revenues, 2010 – 2018 (USD Million)4.1.6 Anti-Infection4.1.6.1 Global anti-infection drugs analysis, number of trials, 2009 - 20124.1.6.2 Global anti-infection peptides market revenues, 2010 – 2018 (USD Million)4.1.7 Neurology4.1.7.1 Global neurology pipeline drugs analysis, number of trials, 2009 - 20124.1.7.2 Global neurology peptides market revenues, 2010 – 2018 (USD Million)4.1.8 Gastro Intestinal4.1.8.1 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 20124.1.8.2 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million)4.1.9 Renal4.1.9.1 Global renal pipeline drugs analysis, number of trials, 2009 - 20124.1.9.2 Global renal peptides market revenues, 2010 – 2018 (USD Million)4.1.10 Respiratory4.1.10.1 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012
  • 7. 4.1.10.2 Global respiratory peptides market revenues, 2010 – 2018 (USD Million)4.1.11 Pain4.1.11.1 Global pain pipeline drugs analysis, number of trials, 2009 - 20124.1.11.2 Global pain peptides market revenues, 2010 - 2018 (USD Million)4.1.12 Others4.1.12.1 Global other pipeline drugs analysis, number of trials, 2009 - 20124.1.12.2 Global other peptides market revenues, 2010 – 2018 (USD Million)Chapter 5 Global Peptide Therapeutics Market, by Route of Administration5.1 Introduction5.1.1 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018(USD Million)5.1.2 Methods of delivery for peptide drugs5.2 Parenteral Route5.2.1 Global peptide therapeutics market revenues, by parenteral route of administration,2010 - 2018 (USD Million)5.3 Oral Route5.3.1 Global peptide therapeutics market revenues, by oral route of administration, 2010 -2018 (USD Million)5.4 Pulmonary Route5.4.1 Global peptide therapeutics market revenues, by pulmonary route of administration,2010 - 2018 (USD Million)5.5 Mucosal Route5.5.1 Global peptide therapeutics market revenues, by mucosal route of administration,2010 - 2018 (USD Million)5.6 Others (Intradermal & Nasal)5.6.1 Global peptide therapeutics market revenues, by other routes of administration, 2010- 2018 (USD Million)Browse Report : http://www.transparencymarketresearch.com/peptide-therapeutics-market.html
  • 8. Chapter 6 Peptide Therapeutics Market – Generic & Innovative Segments6.1 Introduction6.1.1 Global peptide therapeutics market, by types revenues, 2010 - 2018 (USD million)6.2 Peptide Therapeutics – Innovative market6.2.1 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million)6.3 Peptide Therapeutics – Generic market6.3.1 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million)Chapter 7 API Peptide Therapeutics Market, In-house Vs CMO7.1 Introduction7.2 API peptide therapeutics – In-house market7.2.1 Global API peptide therapeutics in-house market revenues, 2010-2018 (USD Million)7.3 Contract Manufacturing Organizations (CMO)7.3.1 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million)Chapter 8 Peptide Therapeutics Market, By Technology8.1 Introduction8.1.1 Global peptide therapeutics market revenues, by technology, 2010 – 2018 (USDMillion)8.2 Solid Phase Peptide Synthesis (SPPS)8.2.1 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USDMillion)8.3 Liquid Phase Peptide Synthesis (LPPS)8.3.1 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USDMillion)8.4 Hybrid Technology8.4.1 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USDMillion)
  • 9. Chapter 9 Peptide Therapeutics Market, By Geography9.1 Introduction9.1.1 Global peptide therapeutics market share, by geography, 2011 - 20189.2 North America9.2.1 North America peptide therapeutics market revenues, 2010 – 2018 (USD Million)9.3 Europe9.3.1 Europe peptide therapeutics market revenues, 2010 – 2018 (USD Million)9.4 Asia9.4.1 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million)9.5 Rest of World9.5.1 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million)Chapter 10 Market Share Analysis10.1 Market share by key players10.2 Market share by key players in peptide drugs market10.2.1 Global peptide therapeutics market share analysis of key players, 2011 (%)10.3 Market share by key players in CMO segment10.3.1 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%)Chapter 11 Recommendations11.1 Success strategies11.1.1 Rigorous research and development (R&D) initiatives11.1.2 Investing in emerging economies11.1.3 Investing in recent technologies such as HPPS TEchnology11.1.4 Mergers and acquisitions11.2 Barriers to be considered11.2.1 The high cost of peptide synthesis
  • 10. 11.2.2 Weak pipeline peptide drug candidates in phase IIIChapter 12 Company Profiles12.1 Bachem Holding AG12.1.1 Company overview12.1.2 Financial overview12.1.3 Strategic overview12.1.3.1 Collaborations12.1.3.2 Expansion12.1.3.3 Divestiture12.1.3.4 Recent developments12.2 Eli Lilly and Company12.2.1 Company overview12.2.2 Financial overview12.2.3 Strategic overview12.2.3.1 Agreements12.2.3.2 Approvals12.2.4 Recent developments12.3 Pfizer, Inc.12.3.1 Company overview12.3.2 Financial overview12.3.3 Strategic overview12.3.3.1 Mergers and acquisitions12.3.3.2 Divestiture12.3.3.3 Approvals12.3.4 Recent developments12.4 Amgen, Inc.
  • 11. 12.4.1 Company overview12.4.2 Financial overview12.4.3 Strategic overview12.4.3.1 Mergers and acquisitions12.4.3.2 Licensing12.4.4 Recent developments12.5 Takeda Pharmaceutical Company Limited12.5.1 Company overview12.5.2 Financial overview12.5.3 Strategic overview12.5.3.1 Partnerships and collaborations12.5.3.2 Mergers and acquisitions12.5.4 Recent developments12.6 Teva Pharmaceuticals12.6.1 Company overview12.6.2 Financial overview12.6.3 Strategic overview12.6.3.1 Mergers and acquisitions12.6.3.2 Investing in generic and biosimilar segments12.6.4 Recent developments12.7 Lonza Inc.12.7.1 Company overview12.7.2 Financial overview12.7.3 Strategic overview12.7.3.1 Investing in emerging economies12.7.3.2 Mergers and acquisitions12.7.4 Recent developments
  • 12. 12.8 Peptisyntha12.8.1 Company overview12.8.2 Financial overview12.8.3 Strategic overview12.8.3.1 Arranging and participating in trade shows12.8.3.2 Continuous manufacturing expansion12.9 Sanofi12.9.1 Company overview12.9.2 Financial overview12.9.3 Strategic overview12.9.3.1 Acquisitions12.9.3.2 Divestments12.9.4 Recent developments12.10 Ipsen12.10.1 Company overview12.10.2 Financial overview12.10.3 Strategic overview12.10.3.1 Large investment in research and development12.10.3.2 Global expansion through partnership12.10.4 Recent developments12.11 PolyPeptide Group.12.11.1 Company overview12.11.2 Strategic overview12.11.2.1 Focus on product portfolio extension and quality product development12.11.2.2 Global expansion through merger and acquisition12.12 Amylin Pharmaceuticals LLC - Bristol-Myers Squibb (BMS)12.12.1 Company overview
  • 13. Browse Report : http://www.transparencymarketresearch.com/peptide-therapeutics-market.html12.12.2 Amylin Pharmaceuticals LLC12.12.3 Financial overview12.12.4 Strategic overview (Amylin Pharmaceuticals LLC)12.12.4.1 Entering into strategic collaborations12.12.4.2 Corporate social responsibility12.12.4.3 Rigorous R&D initiatives12.12.5 Recent developments12.13 AstraZeneca PLC12.13.1 Company overview12.13.2 Financial overview12.13.3 Strategic overview12.13.3.1 Rigorous R&D initiatives12.13.3.2 Investing in emerging economies12.13.4 Recent developments12.14 Roche12.14.1 Company overview12.14.2 Financial overview12.14.3 Strategic overview12.14.3.1 Research and development initiatives12.14.3.2 Focus on personalized healthcare12.14.3.3 Focus on new and emerging markets12.14.3.4 Funding awareness programs12.14.4 Recent developments12.15 GlaxoSmithKline (GSK)
  • 14. 12.15.1 Company overview12.15.2 Financial overview12.15.3 Strategic overview12.15.3.1 Research and development initiatives12.15.3.2 Direct to Consumer Advertising12.15.3.3 Mergers and acquisitions12.15.4 Recent developments12.16 Merck & Co.12.16.1 Company overview12.16.2 Financial overview12.16.3 Strategic overview12.16.3.1 Corporate social responsibility12.16.3.2 R&D Initiatives12.16.3.3 Strategic alliances and out-licensing12.16.4 Recent developments12.17 Novartis AG12.17.1 Company overview12.17.2 Financial overview12.17.3 Strategic overview12.17.3.1 Mergers and acquisitions12.17.3.2 Memorandum of understanding12.17.4 Recent developments12.18 Novo-Nordisk A/S12.18.1 Company overview12.18.2 Financial overview12.18.3 Strategic overview12.18.3.1 Partnerships and alliances
  • 15. 12.18.4 Agreements12.18.5 Recent developmentsAbout Us:Transparency Market Research is a market intelligence company providing global businessinformation reports and services. Our exclusive blend of quantitative forecasting and trendsanalysis provides forward-looking insight for thousands of decision makers.We are privileged with highly experienced team of Analysts, Researchers and Consultants,who use proprietary data sources and various tools and techniques to gather, and analyzeinformation. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:Transparency Market Research90 State Street,Suite 700,AlbanyNY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-552-3453Email: sales@transparencymarketresearch.comWebsite: http://www.transparencymarketresearch.com/